Key result
A three-gene signature (CCL20, IL1R2, ITLN1) effectively distinguished patients with myocardial infarction from healthy controls with a pooled AUC of 0.93, sensitivity of 0.80, and specificity of 0.90.
Why the study?
The diagnostic value of key genes in myocardial infarction using gene expression data had not been fully evaluated.
Does a three-gene signature (CCL20, IL1R2, ITLN1) accurately diagnose myocardial infarction compared to healthy controls?
Meta-Analysis
Does a three-gene signature (CCL20, IL1R2, ITLN1) accurately diagnose myocardial infarction compared to healthy controls?
A three-gene signature consisting of CCL20, IL1R2, and ITLN1 demonstrates high sensitivity and specificity as a novel candidate biomarker for distinguishing myocardial infarction from healthy controls.
Answers are grounded in this paper and cite their sources.
May aid MI diagnosis; extends biomarker research but requires prospective validation before clinical use.
In this study, we evaluated the diagnostic value of key genes in myocardial infarction (MI) based on data from the Gene Expression Omnibus (GEO) database. We used data from GSE66360 to identify a set of significant differentially expressed genes (DEGs) between MI and healthy controls. Logistic regression, least absolute shrinkage and selection operator (LASSO) regression, support vector machine recursive feature elimination (SVM-RFE), and SignalP 3.0 server were used to identify the potential role of genes in predicting diagnosis in patients with MI. Principal component analysis (PCA), receiver operating characteristic (ROC) curve analyses, area under the curve (AUC) analyses, and C-index were used to estimate the diagnostic value of genes in patients with MI. The association was validated using six other independent data sets. Subsequently, bioinformatics analysis was conducted based on the aforementioned potential genes. A meta-analysis was performed to evaluate the diagnostic value of the genes in MI. Forty-four DEGs were selected from the GSE66360 dataset. A three-gene signature consisting of CCL20, IL1R2, and ITLN1 could effectively distinguish patients with MI. The three-gene signature was validated in seven independent cohorts. Functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to reveal the involvement of the three-gene signature in inflammation-related biological processes and pathways. Moreover, diagnostic meta-analysis results of the three-gene signature showed that the pooled sensitivity, specificity, and AUC for MI were 0.80, 0.90, and 0.93, respectively. These results suggest that the three-gene signature is a novel candidate biomarker for distinguishing MI from healthy controls.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2021) conducted a meta-analysis in Myocardial infarction. Three-gene signature (CCL20, IL1R2, and ITLN1) vs. Healthy controls was evaluated on Diagnosis of myocardial infarction (AUC 0.93). A three-gene signature (CCL20, IL1R2, ITLN1) effectively distinguished patients with myocardial infarction from healthy controls with a pooled AUC of 0.93, sensitivity of 0.80, and specificity of 0.90.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: